Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

References for PMC Articles for PubMed (Select 21555763)

1.

Colistin dosing and nephrotoxicity in a large community teaching hospital.

Deryke CA, Crawford AJ, Uddin N, Wallace MR.

Antimicrob Agents Chemother. 2010 Oct;54(10):4503-5. doi: 10.1128/AAC.01707-09. Epub 2010 Jul 26.

2.

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Dudhani RV, Turnidge JD, Nation RL, Li J.

J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23.

3.

Removal of colistin during intermittent haemodialysis in two critically ill patients.

Marchand S, Frat JP, Petitpas F, LemaƮtre F, Gobin P, Robert R, Mimoz O, Couet W.

J Antimicrob Chemother. 2010 Aug;65(8):1836-7. doi: 10.1093/jac/dkq185. Epub 2010 May 25. No abstract available.

4.

Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage.

Dudhani RV, Nation RL, Li J.

J Antimicrob Chemother. 2010 Jul;65(7):1412-5. doi: 10.1093/jac/dkq134. Epub 2010 Apr 22.

5.

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL.

Antimicrob Agents Chemother. 2010 Mar;54(3):1117-24. doi: 10.1128/AAC.01114-09. Epub 2009 Dec 22.

6.

Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients?

Opal SM, Calandra T.

JAMA. 2009 Dec 2;302(21):2367-8. doi: 10.1001/jama.2009.1774. No abstract available.

PMID:
19952325
7.

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G.

Clin Infect Dis. 2009 Jun 15;48(12):1724-8. doi: 10.1086/599225.

8.

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6. doi: 10.1128/AAC.01361-08. Epub 2009 May 11.

9.

Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS.

Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE.

J Pharm Biomed Anal. 2009 Apr 5;49(3):760-7. doi: 10.1016/j.jpba.2008.12.016. Epub 2008 Dec 24.

PMID:
19157746
10.

Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G.

Clin Ther. 2008 Jan;30(1):143-51. doi: 10.1016/j.clinthera.2008.01.015.

PMID:
18343250
11.

High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea.

Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH.

J Antimicrob Chemother. 2007 Nov;60(5):1163-7. Epub 2007 Aug 29.

13.

Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster.

Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H.

J Antimicrob Chemother. 2007 Apr;59(4):786-90. Epub 2007 Feb 16.

14.

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL.

Lancet Infect Dis. 2006 Sep;6(9):589-601. Review.

PMID:
16931410
15.

Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Bergen PJ, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2006 Jun;50(6):1953-8.

16.

Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin.

Beno P, Krcmery V, Demitrovicova A.

Clin Microbiol Infect. 2006 May;12(5):497-8. No abstract available.

17.

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Clin Infect Dis. 2006 Mar 1;42(5):657-68. Epub 2005 Jan 25. Review. Erratum in: Clin Infect Dis. 2006 Apr 1;42(7):1065.

18.

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H.

J Antimicrob Chemother. 2006 Feb;57(2):306-11. Epub 2006 Jan 5.

19.

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N, Douglas A, Lipman J.

Antimicrob Agents Chemother. 2005 Nov;49(11):4814-5. No abstract available.

20.

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Falagas ME, Kasiakou SK.

Clin Infect Dis. 2005 May 1;40(9):1333-41. Epub 2005 Mar 22. Review. Erratum in: Clin Infect Dis. 2006 Jun 15;42(12):1819. Dosage error in article text.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk